PBAC's latest decision on Moxonidine: Recommended with restriction (2006). Considered for Treatment of hypertension in patients receiving concurrent antihypertensive therapy.
PBAC outcome
Recommended with restriction
Restricted Benefit
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2006
Submissions
1
2006 → 2006
Eligible population
Hypertension in patients receiving concurrent antihypertensive therapy.
Therapy area
Cardiovascular
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
Other
Key trials
Plänitz (1987), Plänitz (1984), Plänitz (1985)
Comparator
clonidine
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis used; no ICER calculated